Predicting a window of therapeutic opportunity in multiple sclerosis

Brain

Volumn 133, Issue 7, 2010, Pages 1863-1865

  Andersen, Oluf ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOLIPID; GLYCOPROTEIN; MYELIN;

BLOOD BRAIN BARRIER; DISEASE COURSE; HUMAN; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NOTE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; SURVIVAL;

EID: 77954380793     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq182     Document Type: Note

References (18)

1. Charcot J-M. Septième lecon. Lecons sur les maladies du système nerveux. Paris; 1877. p. 221-247
2. Coles A, Cox A, Le Page E, Jones J, Trip SA, Deans J, et al. The window of therapeutic opportunity in multiple sclerosis. Evidence from monoclonal antibody therapy. J Neurol 2006; 253: 98-108.
3. Confavreux C, Vukusic S, Adelaine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis; an amnesic process. Brain 2003; 126: 770-782
4. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain 2006; 129: 595-605.
5. Eriksson M, Andersen O, Runmarker B. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 2003; 9: 260-274
6. Garbern JY, Yool DA, Moore GJ, Wilds IB, Faulk MW, Klugmann M, et al. Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation. Brain 2002; 125: 551-561
7. Hauser S, Oksenberg J. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006; 52: 61-76.
8. Kanter J, Narayana S, Ho P, Catz I, Warren K, Sobel R, et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med 2006; 12: 138-143
9. Kremenchutzky M, Rice GPA, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 9: Observations on the progressive phase of the disease. Brain 2006; 129: 584-594
10. Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010; 133: 1900-1913
11. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907-911
12. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130: 1089-1104.
13. Müller R. Studies in disseminated sclerosis. Acta Med Scand 1949; 133: 1-214.
14. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993; 116: 117-134
15. Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain 2010; 133: 1914-1929.
16. Trapp B, Bö L, Mörk S, Chang A. Pathogenesis of tissue injury in MS lesions. J Neuroimmunol 1999; 98: 49-56.
17. Tremlett H, Yousefi M, Devonshire V, Riekmann P, Zhao Y. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 2009; 73: 1616-1623
18. Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain 1989; 112: 133-146 (Pubitemid 19056478)